Member Info for DD77

Alright Captain Mainwaring calm down. It's just following the FTSE movements.

If you're not comfortable with stock market movements, I suggest you put your capital into a cash ISA

It was an ok update. Renewal rate drop was disappointing, but nice new contract win, albeit small.

Pipeline is encouraging but the key is converting that into hard sales. If that's achieved, this will go well in 2024/5. Commercialisation is key.

Https://www.bbc.co.uk/news/business-67994140

Things not looking good for Ryanair. Tied in with Boeing who are in a mess, openly admitting that deliver delays are hindering their capacity and saying Ryanair don’t have confidence in Boeing’s quality control measures!

Very encouraging business update, a lot of exciting pipeline projects and cash burn better than expected.

No near term cash concerns and commercial discussions ongoing. What’s more is the ETX platform looks to have now been proven. 2024 could be a transformative year if those major commercial deals land as expected

Have to agree Jason, unfortunately. I don't see myself executing my warrants..................there's nothing to convince me that this has a chance of making it a profitable company

Good write up and interview. Worth a read

https://www.proactiveinvestors.co.uk/companies/news/1038104/c4xd-a-biotechnology-pioneer-in-immuno-inflammation-1038104.html

i did love the positive spin put by epstein on the failed raise.

they're **** out of luck, they've thrown their last dice and the numbers haven't come up. now they're on the home straight to administration. 2024 mos rip

As posted on 9th Jan by myself:

So how much of the £300k do you think will be raised? Place your bets now..............

I think they'll struggle to raise half that with the SP hovering below.

Given the lack of alternative opinions, which was disappointing, I will take the prize of the correct answer :)

Thanks, was just about to look up!

So probably no immediate impact for Wizz. We await Q3 results with interest

So how much of the £300k do you think will be raised? Place your bets now..............

I think they'll struggle to raise half that with the SP hovering below.

I remember when Nigel Burton reassured me at the last fund raise, that this was to get them to break even point and no further fund raises would be required. I'm glad I didn't invest further on that basis

My question remains, which European competitors have the 737 MAX? I can do some digging if others don’t know. I think Norwegian do.

This is a major issue with the model now and I can’t see it being approved to fly again anytime soon so this potentially creates a huge opportunity for Wizz to capitalise. There will be a shortage of aircraft now for sure into the summer. The US market will particularly be hit

Given this is a Tiziana bulletin board, I would imagine that most people who visit this page are interested in its news.

As for Accustem, I suggest you email the board if you would like to find out further

New RNS update:

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.

Tarun Singhal, M.B.B.S., M.D., Director of PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, commented, “Upon review of the baseline and three-month [F-18] PBR06 PET scans of the two new na-SPMS EA patients, a qualitative reduction in microglial activity was seen in one of two new patients. When combined with my assessment of the first six EA patients at three-months, a total of six out of the eight suggested a reduction in qualitative microglial PET signal. These findings are promising from an imaging standpoint and further studies are needed to confirm them using additional quantitative approaches.”

“The EA patient having a qualitative improvement in their PET scan also improved in their Modified Fatigue Impact Scale,” stated Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women’s Hospital. “Six out of the eight na-SPMS EA patients studied so far have seen measurable clinical improvement in their fatigue. I am excited to lead the effort to replicate these findings in the ongoing Phase 2 dose-ranging, randomized, placebo-controlled clinical trial.”

Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences noted “We’ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where intranasal foralumab targets inflammation in the brain. It is my expectation that we will rapidly progress our ongoing Phase 2 trial of intranasal foralumab, given the encouraging results seen so far under the EA IND."

https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-updated-clinical-and-pet-scan

I’m wondering if any of Wizz competitors have the 737 max? I know Ryanair have a lot of Boeing aircraft but not sure on the models

I disagree, 4 weeks is long enough to raise capital, they could have been working on this in the background. But unless they have some commercial deal lined up, it's unlikely to succeed.

This is as likely to go into administration as it is to continue, if not more likely. Place your bets

Thanks for sharing.

I concur that this rise is more than just reassurance on funding requirements - it is further validation of the tech, and an important value inflection point. The 3 days of consecutive strong SP rises on heavy trading demonstate that.

With a Sanofi milestone payment imminent and further deals in the pipeline, I expect a big 2024. This was above 40p a couple of years ago. I expect it to rise significantly above that

We believe the risk reduction could be substantial with combination therapy.”

Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.

Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597). SELECT showed a 20% reduction of major adverse cardiovascular events (MACE) such as heart attack, stroke, and peripheral vascular disease, with semaglutide. The risk of adverse cardiovascular events could be reduced further by the combination of intranasal foralumab and a GLP-1ra. The patent application describes the potential for foralumab to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease. Foralumab given with GLP-1ra may contribute importantly to further risk reduction in this at-risk patient population.

“The GLP-1ra’s have revolutionized the treatment of obesity and type 2 diabetes. Obesity and type 2 diabetes are associated with inflammation in the liver, adipose and vascular tissue. This inflammation contributes to the pathogenesis of stroke,” commented Howard L. Weiner M.D. from Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System and Professor of Neurology. “Although effective, GLP-1ra’s do not completely mitigate the disease process and are associated with various side effects. Intranasal foralumab, a fully human anti-CD3, has shown efficacy in attenuating inflammation in humans with multiple sclerosis and COVID. Because intranasal foralumab induces regulatory T cells in a physiologic fashion, foralumab has novel anti-inflammatory properties that make it applicable to multiple disease conditions. Furthermore, it has had minimal side effects in both human and animal studies. We have now discovered intranasal anti-CD3’s positive effect in models of diet-induced obesity related to mitigating its complications. Intranasal anti-CD3 therapy also dramatically decreases inflammation and metabolic changes. Thus, we believe it has the potential to be an ideal therapy to be given in combination with the class of GLP-1ra approved drugs.”

Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences said, “I believe that our commitment to improving patient outcomes by using anti-CD3, or foralumab, in risk mitigation for MACE could be another exciting indication for foralumab. We hope our efforts will give a new therapeutic option to patients afflicted with Type 2 Diabetes and non T2D obesity that are receiving GLP-1 receptor antagonists. We believe the risk reduction could be substantial with com

Yes, correct FiveCandles, they tried to raise last year and didn't get enough interest. This looks like last chance saloon for them................so people should be aware and not blindly follow others into here. It's a massive risk

Watch out for those scammers who claim RENE has £5m in cash. It doesn't. That's what it had in September. With cash burn, it needs to raise before April if no new revenues. It's clearly stated in the interims, for those who are too dumb to research:

At 30 September 2023, the Group had cash, cash equivalents and bank deposits of £5.1 million with the Group's latest internal projections (assuming no new revenues or funding) showing a cash runway to April 2024, ahead of which point further revenues and/or a capital injection will be required.